The use of protease inhibitor in multiple myeloma patients who refractory to bortezomib

Phase 1

Recruiting

• Conditions: Relapsed or relapsed and refractory multiple myelomaPrior treated with bortezomib; Multiple myeloma; Protease inhibitor; Relapsed multiple myeloma; Relapsed and refractory multiple myeloma

• Registration Number: TCTR20211027004
• Lead Sponsor: Chalermphrakiat Grant, Faculty of Medicine Siriraj Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-27
• Last Update Posted: 19 August 2024
• Study Completion: 2028-03-27

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Relapsed or relapsed and refractory multiple myeloma
Prior treated with bortezomib
Measurable disease: M-protein > 0.5 g/dL

Exclusion Criteria

Severe allergy to protease inhibitor
Requiring administration strong CYP3A4 metabolized drugs
active infection
peripheral neuropathy more than grade 2

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety 1 year Percentage

Secondary Outcome Measures

Name	Time	Method
response rate 12 months Percentage